The work, published in Molecular Cancer, addresses a long-standing frustration in tumor biology. Cancer-associated fibroblasts, or CAFs, have been recognized for decades as central players in stromal remodeling, immune exclusion, and drug resistance, but most classifications of these cells have been static snapshots. Pathologists and single-cell biologists could label fibroblasts as myofibroblastic, inflammatory, or antigen-presenting subtypes, yet the field lacked a causal account of how tumor cells instruct fibroblasts to adopt these pathogenic identities in the first place. The new study set out to answer precisely that question: does the tumor merely coexist with certain fibroblast states, or does it actively manufacture them?

To map the landscape, the team performed integrative single-cell RNA sequencing on lung adenocarcinoma specimens, constructing a detailed stromal atlas of the disease and tracing fibroblast lineage trajectories. Rather than falling into discrete categories, fibroblasts in these tumors followed a continuous differentiation path that converged on a myofibroblast-like endpoint marked by MMP11 expression. This MMP11-positive subset carried a transcriptional program dominated by extracellular matrix remodeling and collagen organization, and its gene-expression signature overlapped strongly with markers of immune exclusion. Across multiple independent patient cohorts, the abundance of this fibroblast state tracked with worse clinical outcomes, suggesting it is not a bystander but an active participant in disease progression.

The next question was mechanistic: what turns ordinary fibroblasts into MMP11-producing matrix builders? The researchers co-cultured tumor cells with fibroblasts and found that different lung adenocarcinoma cell lines varied dramatically in their ability to trigger the program. When they separated the tumor cells’ influence into soluble factors and extracellular vesicles, the vesicle fraction carried most of the programming activity. Extracellular vesicles are nanoscale lipid-enclosed particles that cells release to shuttle proteins, lipids, and nucleic acids to recipient cells, functioning as a kind of biological postal system. Using isolation and functional fractionation techniques, the team demonstrated that removing vesicles from tumor-conditioned media largely abolished the induction of the MMP11-positive state, while purified vesicles restored it.

To identify the cargo responsible, the researchers turned to quantitative proteomics of the vesicles themselves, comparing vesicles with high CAF-programming activity against those with low activity using both data-dependent and data-independent acquisition mass spectrometry. One protein stood out: secreted phosphoprotein 1, better known as SPP1 or osteopontin, a secreted glycoprotein previously implicated in metastasis and immune regulation. SPP1 was selectively enriched in the vesicles that most potently drove fibroblast reprogramming, indicating that the tumor does not simply dump a generic mix of molecules into its vesicles but actively sorts specific signaling proteins into them.

The mechanistic chain was then traced to its receptor. Vesicle-associated SPP1, the study found, engages primarily the CD44 receptor on the surface of fibroblasts. This binding activates the PI3K-AKT signaling pathway, a canonical pro-survival and pro-growth cascade, and sustains the transcriptional changes that push fibroblasts into the MMP11-positive phenotype. Genetic and pharmacologic perturbations confirmed the pathway’s causality: blocking SPP1, CD44, or PI3K-AKT signaling prevented the fibroblast reprogramming in co-culture systems. In other words, the tumor-to-stroma communication is not diffuse background noise but a specific, druggable ligand-receptor axis.

The clinical implications emerged clearly from multiplex immunofluorescence staining of lung adenocarcinoma specimens. Tumors rich in MMP11-positive fibroblasts showed dense collagenous matrix deposition, physical exclusion of T cells from the tumor nests, and reduced intratumoral immune infiltration. In cohorts of patients treated with chemo-immunotherapy, the presence of this fibroblast state predicted poorer responses, consistent with the idea that a matrix-rich, immune-excluded microenvironment undermines the ability of checkpoint inhibitors to mobilize anti-tumor T cells. The findings thus provide a mechanistic bridge between a specific stromal cell state and the well-known clinical problem of immunotherapy resistance in lung cancer.

Crucially, the study went beyond correlation and tested whether interrupting the EV-SPP1 axis could reverse the process in living organisms. In immunocompetent mouse models of lung tumor growth and metastasis, disrupting the pathway reduced the development of MMP11-positive CAFs, loosened the dense stromal architecture, and revived anti-tumor T-cell immunity. Most strikingly, combining EV-SPP1 pathway disruption with PD-1 immune checkpoint blockade made tumors substantially more sensitive to the immunotherapy, transforming a resistant microenvironment into one that immune cells could penetrate and attack. This positions the vesicle cargo protein not just as a biomarker but as a candidate therapeutic target in its own right.

The broader significance of the work lies in reframing how scientists think about the tumor microenvironment. Rather than treating fibroblast diversity as an intrinsic property of stromal cells, the study shows that tumor cells can actively author the identity of their neighbors through targeted vesicle-mediated delivery of signaling proteins. This tumor-instructed model of stromal reprogramming suggests that effective immunotherapy strategies in lung adenocarcinoma may need to target the communication lines between cancer cells and fibroblasts, not only the immune checkpoints themselves. If the EV-SPP1-CD44-PI3K-AKT circuit can be safely intercepted in patients, it could convert a large fraction of immune-excluded, therapy-resistant lung tumors into ones that respond to existing treatments, offering a rational path to combination regimens built on the biology of intercellular vesicle trafficking.

Subject of Research: Tumor-derived extracellular vesicle SPP1 programming of MMP11-positive cancer-associated fibroblasts driving immune exclusion in lung adenocarcinoma

Article Title: Extracellular vesicle–enriched SPP1 programs MMP11⁺ fibroblast states to drive immune exclusion in lung adenocarcinoma

Article References: He, X., Qian, L., Zhao, D., Wang, G., Zhang, X., Ye, Y., Li, L., Wen, Y., & Zhang, L. (2026). Extracellular vesicle–enriched SPP1 programs MMP11⁺ fibroblast states to drive immune exclusion in lung adenocarcinoma. Molecular Cancer. https://doi.org/10.1186/s12943-026-02785-5

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02785-5

Keywords: lung adenocarcinoma, cancer-associated fibroblasts, extracellular vesicles, SPP1, MMP11, immune exclusion, tumor microenvironment, immunotherapy resistance, PD-1 blockade, PI3K-AKT signaling, CD44, single-cell RNA sequencing